Amiodarone modulates pharmacokinetics of low-dose methotrexate in rats

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 5, 2008, Pages 289-299

  Fuksa, Leos ^a   Brcakova, Eva ^a   Cermanova, Jolana ^a   Hroch, Milos ^a   Chladek, Jaroslav ^a   Kolouchova, Gabriela ^a   Malakova, Jana ^c   Martinkova, Jirina ^a   Staud, Frantisek ^b   Micuda, Stanislav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Amiodarone; Azithromycin; Biliary excretion; Interaction; Methotrexate

Indexed keywords

AMIODARONE; AZITHROMYCIN; BILIRUBIN GLUCURONIDE; METHOTREXATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG SAFETY; DRUG URINE LEVEL; EXPERIMENTAL MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERBILIRUBINEMIA; KIDNEY CLEARANCE; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

AMIODARONE; ANIMALS; AZITHROMYCIN; BILE; DRUG ANTAGONISM; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; METHOTREXATE; RATS; RATS, WISTAR;

EID: 48449099277     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.614     Document Type: Article

References (46)

1. Grim J, Chladek J, Martinkova. J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet 2003; 42: 139-151.
2. Chladek J, Grim J, Martinkova J, et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol 2002; 54: 147-156.
3. Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996; 30: 194-210.
4. Singh BN. Amiodarone: a multifaceted antiarrhythmic drug. Curr Cardiol Rep 2006; 8: 349-355.
5. Roden DM. Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol 1993; 72: 45F-50F.
6. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 2006; 49: 244-253.
7. Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003; 26: 421-438.
8. Robinson K, Johnston A, Walker S, Mulrow JP, McKenna WJ, Holt DW. The digoxin-an-dodarone interaction. Cardiovasc Drugs Ther 1989; 3: 25-28.
9. van der Graaf WT, Buter J, de Vries EG, Willemse PH, Sleijfer DT, Mulder NH. High dose oral amiodarone added to doxorubicin and vindesine for overcoming multidrug resistance in solid tumors. Ann Oncol 1994; 5: 659-660.
10. Kakumoto M, Takara K, Sakaeda T, Tanigawara Y, Kita T, Okumura K. MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs. Biol Pharm Bull 2002; 25: 1604-1607.
11. Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci 2001; 12: 505-513.
12. Kodawara T, Masuda S, Wakasugi H, et al. Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharm Res 2002; 19: 738-743.
13. Reynolds NJ, Jones SK, Crossley J, Harman RR. Methotrexate induced skin necrosis: a drug interaction with amiodarone? Br Med J 1989; 299: 980-981.
14. Jain R, Danziger LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 2004; 10: 3045-3053.
15. Zhanel GG, Dueck M, Hoban DJ, et al. Review of macrolides; and ketolides: focus on respiratory tract infections. Drugs 2001; 61: 443-498.
16. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 (Suppl A): 73-82.
17. Sugie M, Asakura E, Zhao YL, et al. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother 2004; 48: 809-814.
18. Asakura E, Nakayama H, Sugie M, et al. Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol 2004; 484: 333-339.
19. Masuda M, I'izuka Y, Yamazaki M, et al. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res 1997; 57: 3506-3510.
20. Thyss A, Milano G, Renee N, Cassuto-Viguier E, Jambou P, Soler C. Severe interaction between methotrexate and a macrolide-like antibiotic. J Natl Cancer Inst 1993; 85: 582-583.
21. Cermanova J, Micuda S, Brcakova E, et al. Influence of azithromycin on hepatobiliary and renal excretion of methotrexate in rats. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007; 151 (Suppl 1): 14-16.
22. Shayeganpour A, Jun AS, Brocks DR. Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fatmeal rat models. Biopharm Drug Dispos 2005; 26: 249-257.
23. Ghibellini G, Vasist LS, Hill TE, Heizer WD, Kowalsky RJ, Brouwer KL. Determination of the biliary excretion of piperacillin in humans using a novel method 3. Br J Clin Pharmacol 2006; 62: 304-308.
24. Nuernberg B, Koehnke R, Solsky M, Hoffman J, Furst DE. Biliary elimination of low-dose methotrexate in humans. Arthritis Rheum 1990; 33: 898-902.
25. Hulot JS, Villard E, Maguy A, et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 2005; 15: 277-285.
26. Chen C, Scott D, Hanson E, et al. Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats. Pharm Res 2003; 20: 31-37.
27. Fahrig L, Brasch H, Iven H. Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX. Cancer Chemother Pharmacol 1989; 23: 156-160.
28. Wyss PA, Moor MJ, Bickel MH. Single-dose kinetics of tissue distribution, excretion and metabolism of amiodarone in rats. J Pharmacol Exp Ther 1990; 254: 502-507.
29. Luke DR, Foulds G, Cohen SF, Levy B. Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob Agents Chemother 1996; 40: 2577-2581.
30. Jacobs RF, Maples HD, Aranda JV, et al. Pharmacokinetics of intravenously administered azithromycin in pediatric patients. Pediatr Infect Dis J 2005; 24: 34-39.
31. Achira M, Totsuka R, Kume T. Decreased activity of hepatic P-glycoprotein in the isolated perfused liver of the adjuvant arthritis rat. Xenobiotica 2002; 32: 963-973.
32. Chandra P, Brouwer KL. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 2004; 21: 719-735.
33. Badagnani I, Castro RA, Taylor TR, et al. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 2006; 318: 521-529.
34. Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 432-443.
35. Ueda K, Kato Y, Komatsu K, Sugiyama Y. Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J Pharmacol Exp Ther 2001; 297: 1036-1043.
36. Morales AI, Barata JD, Bruges M, et al. Acute renal toxic effect of amiodarone in rats. Pharmacol Toxicol 2003; 92:39-42.
37. McBroorn JW. Medical management of interstitial pregnancy with a retained IUD. A case report. J Reprod Med 2000; 45: 490-492.
38. Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007; 35: 779-786.
39. Kamisako T, Kobayashi Y, Takeuchi K, et al. Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance. J Gastroenterol 2000; 35: 659-664.
40. Chang CC, Petrelli M, Tomashefski JF, Jr, McCullough AJ. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature. Arch Pathol Lab Med 1999; 123: 251-256.
41. Chandrupatla S, Demetris AJ, Rabinovitz M. Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci 2002; 47: 2186-2188.
42. Ferguson J, Addo HA, Jones S, Johnson BE, Frain-Bell W. A study of cutaneous photosensitivity induced by amiodarone. Br J Dermatol 1985; 113: 537-549.
43. Reinhart WH, Rohner F. Effect of amiodarone on erythrocyte shape and membrane properties. Clin Sci (Lond) 1990; 79: 387-391.
44. Mayr AJ, Dunser MW, Ritsch N, et al. Fligh-dosage continuous amiodarone therapy to treat new-onset supraventricular tachyarrhythmias in surgical intensive care patients: an observational study. Wien Klin Wochenschr 2004; 116: 310-317.
45. Zelcer N, van de Wetering K, de Waart R, et al. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol 2006; 44: 768-775.
46. Borst P, de Wolf C, van de Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch 2007; 453: 661-673.